Posting this under the heading it deserves: Second pass at: Cross-border purchase within the EU: the actual rules Everything below is what sits behind that.
The question about Cross-border purchase within that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.
The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.
Picking up post #4: that is the part I would want checked first.
The honest answer on Cross-border purchase within is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
On post #6 — agreed on the reasoning, with one qualification.
I read the earlier replies on Cross-border purchase within twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Since Cross-border purchase within keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.
On post #9 — agreed on the reasoning, with one qualification.
Counterpoint on Cross-border purchase within, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Grateful for the specificity. Vague answers to this question are what sent me looking.
Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
Post #13 describes the usual case. This is about the unusual one.
Summarising the Cross-border purchase within thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
A note on how Cross-border purchase within gets discussed rather than on Cross-border purchase within itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Post #17 answers the question as asked. The question underneath it is different.
Import rules for personal quantities are jurisdiction-specific and change without much publicity. Establishing your own position is unavoidable.
If that reads as pedantic, it is, and it has saved me twice.
Post #20 and I disagree about the size of the effect, not about the direction.
Where the Cross-border purchase within discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Narrowing post #22, because the general version has more than one answer.
Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.
That holds for the case as described. Change the assumptions and it may not.
This follows post #22 rather than contradicting it.
Customs practice varies between entry points within the same country, which is why two people in the same jurisdiction report different experiences honestly.
Worth reading the earlier posts in this thread before acting on mine.
Worth separating two things that post #24 runs together.
If you are new and reading this thread for the answer to Cross-border purchase within: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Sensible. I would want the same detail before I acted on it either.
Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).